Renal expression of PLA2R, THSD7A, and IgG4 in patients with membranous nephropathy and correlation with clinical findings.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
revised:
03
11
2020
received:
24
09
2020
accepted:
20
11
2020
pubmed:
30
11
2020
medline:
28
4
2021
entrez:
29
11
2020
Statut:
ppublish
Résumé
Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in nondiabetic adults. M-type phospholipase A2 receptor (PLA2R), thrombospondin type-1 domain-containing 7A (THSD7A) are known as target podocyte antigens in membranous nephropathy (MN). Antibodies against these podocyte antigens are used in the initiation of treatment and response monitoring. However, the relationship between renal podocyte antigens and treatment response is not clear yet. We evaluated the relationship between immunohistochemical PLA2R, THSD7A and IgG4 staining, clinical findings and treatment response in kidney biopsies. Fifty-eight patients with MN were included in this retrospective study. In the renal biopsy samples of the patients, PLA2R, THSD7A and IgG4 were stained immunohistochemically and evaluated by light microscopy. The clinical, laboratory and treatment results of the patients were obtained from the hospital records. The study included a total of 58 patients with MN and a mean follow-up period of 32.3 ± 19.7 months. In patients with primary MN; PLA2R, THSD7A and IgG4 were positive in 57.1% (n = 28), 12.2% (n = 6) and 69.4% (n = 34), respectively. Only PLA2R staining was distinctly higher in patients with primary MN than secondary MN (P = .025). Dual positivity (PLA2R + THSD7A) was detected in five (10.2%) of patients with primary MN. We did not determine any relationship between the PLA2R, THSD7A and IgG4 staining patterns and treatment response of the patients. It was found no correlation between PLA2R, THSD7A and IgG4 staining in kidney tissue and treatment response. Interestingly, dual positivity (PLA2R + THSD7A) was detected only in primary MN.
Sections du résumé
BACKGROUND
BACKGROUND
Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in nondiabetic adults. M-type phospholipase A2 receptor (PLA2R), thrombospondin type-1 domain-containing 7A (THSD7A) are known as target podocyte antigens in membranous nephropathy (MN). Antibodies against these podocyte antigens are used in the initiation of treatment and response monitoring. However, the relationship between renal podocyte antigens and treatment response is not clear yet. We evaluated the relationship between immunohistochemical PLA2R, THSD7A and IgG4 staining, clinical findings and treatment response in kidney biopsies.
METHODS
METHODS
Fifty-eight patients with MN were included in this retrospective study. In the renal biopsy samples of the patients, PLA2R, THSD7A and IgG4 were stained immunohistochemically and evaluated by light microscopy. The clinical, laboratory and treatment results of the patients were obtained from the hospital records.
RESULTS
RESULTS
The study included a total of 58 patients with MN and a mean follow-up period of 32.3 ± 19.7 months. In patients with primary MN; PLA2R, THSD7A and IgG4 were positive in 57.1% (n = 28), 12.2% (n = 6) and 69.4% (n = 34), respectively. Only PLA2R staining was distinctly higher in patients with primary MN than secondary MN (P = .025). Dual positivity (PLA2R + THSD7A) was detected in five (10.2%) of patients with primary MN. We did not determine any relationship between the PLA2R, THSD7A and IgG4 staining patterns and treatment response of the patients.
CONCLUSION
CONCLUSIONS
It was found no correlation between PLA2R, THSD7A and IgG4 staining in kidney tissue and treatment response. Interestingly, dual positivity (PLA2R + THSD7A) was detected only in primary MN.
Substances chimiques
Autoantibodies
0
Immunoglobulin G
0
PLA2R1 protein, human
0
Receptors, Phospholipase A2
0
THSD7A protein, human
0
Thrombospondins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13855Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol. 2008;3(3):905-919.
Lai WL, Yeh TH, Chen PM, et al. Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment. J Formos Med Assoc. 2015;114(2):102-111.
Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-997.
Zhang YZ, Lee HS. Quantitative changes in the glomerular basement membrane components in human membranous nephropathy. J Pathol. 1997;183(1):8-15.
Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020;97(1):163-174.
Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21.
Tomas NM, Beck LH, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277-2287.
Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286-1291.
Oh YJ, Yang SH, Kim DK, Kang SW, Kim YS. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One. 2013;8(4):e62151.
Hoxha E, Kneißler U, Stege G, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012;82(7):797-804.
De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28(2):421-430.
Guo N, Cao Y, Dai H, Yuan L, Shi L, Zhang Y. Anti-phospholipase A2 receptor (Anti-PLA2R) antibody in diagnosis and treatment of idiopathic membranous nephropathy: a single-center observational study in China. Med Sci Monit. 2019;25:9364-9368.
Jullien P, Seitz Polski B, Maillard N, et al. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy. Clin Kidney J. 2017;10(2):209-214.
Xie Q, Li Y, Xue J, et al. Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol. 2015;41(4-5):345-353.
Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364(7):689-690.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
Debiec H, Ronco P. Immunopathogenesis of membranous nephropathy: an update. Semin Immunopathol. 2014;36(4):381-397.
Kao L, Lam V, Waldman M, Glassock RJ, Zhu Q. Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy. J Am Soc Nephrol. 2015;26(2):291-301.
Sugahara G, Kamiie J, Kobayashi R, Mineshige T, Shirota K. Expression of phospholipase A2 receptor in primary cultured podocytes derived from dog kidneys. J Vet Med Sci. 2016;78(5):895-899.
Zhu SS, Zhou SL, Zhou CM, Li YQ, Zou HQ. Detection of PLA2R1 in renal biopsy specimens of patients with idiopathic membranous nephropathy. Nan Fang Yi Ke Da Xue Xue Bao. 2015;35(4):526-529.
Gopalakrishnan N, Abeesh P, Dineshkumar T, et al. Prevalence of serum anti M-type phospholipase A2 receptor antibody in primary membranous nephropathy: a single center experience. Indian J Nephrol. 2016;26(4):257-261.
Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant. 2013;28(7):1839-1844.
Qin H-Z, Zhang M-C, Le W-B, et al. Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy. J Am Soc Nephrol. 2016;27(10):3195-3203.
Zhang D, Zou J, Zhang C, Zhang W, Lin F, Jiang G. Clinical and histological features of phospholipase A2 receptor-associated and thrombospondin type-I domain-containing 7A-associated idiopathic membranous nephropathy: a single center retrospective study from China. Med Sci Monit. 2018;24:5076-5083.
Iwakura T, Ohashi N, Kato A, Baba S, Yasuda H. Prevalence of Enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy. PLoS One. 2015;10(9):e0138841.
Wang J, Xie Q, Sun Z, et al. Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study. BMC Nephrol. 2017;18(1):227.
Dong D, Fan TT, Wang YY, Zhang L, Song L, Zhang L. Relationship between renal tissues phospholipase A2 receptor and its serum antibody and clinical condition and prognosis of idiopathic membranous nephropathy: a meta-analysis. BMC Nephrol. 2019;20(1):444.
Pang LU, Zhang A-M, Li H-X, et al. Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: a cross-sectional study. Medicine. 2017;96(24):e7218.
Wei S-Y, Wang Y-X, Li J-S, et al. Serum anti-PLA2R Antibody predicts treatment outcome in idiopathic membranous nephropathy. Am J Nephrol. 2016;43(2):129-140.
Haas M. IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies. Am J Kidney Dis. 1994;23(3):358-364.
Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant. 2004;19(3):574-579.
Liu L, Chang B, Wu X, Guo Y, Pan Y, Yang L. Expression of phospholipase A2 receptor and IgG4 in patients with membranous nephropathy. Vasc Health Risk Manag. 2018;14:103-108.
Hara S, Tsuji T, Fukasawa Y, et al. Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. Virchows Arch. 2019;474(6):735-743.
Hoxha E, Beck LH, Wiech T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol. 2017;28(2):520-531.
Hoxha E, Wiech T, Stahl PR, et al. A mechanism for cancer-associated membranous nephropathy. N Engl J Med. 2016;374(20):1995-1996.
Zhang C, Zhang M, Chen D, et al. Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy. J Clin Pathol. 2019;72(10):705-711.
Larsen CP, Cossey LN, Beck LH. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Mod Pathol. 2016;29(4):421-426.